Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132


Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.

Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM.

J Immunother. 2014 May;37(4):193-203. doi: 10.1097/CJI.0000000000000014.


Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE, Rooney CM.

Blood. 2003 Mar 1;101(5):1905-12.


Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.

Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.

Eur J Immunol. 2006 Mar;36(3):593-602.


Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304.


Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.

Fogg MH, Wirth LJ, Posner M, Wang F.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3318-23. doi: 10.1073/pnas.0813320106.


A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.

Taylor GS, Jia H, Harrington K, Lee LW, Turner J, Ladell K, Price DA, Tanday M, Matthews J, Roberts C, Edwards C, McGuigan L, Hartley A, Wilson S, Hui EP, Chan AT, Rickinson AB, Steven NM.

Clin Cancer Res. 2014 Oct 1;20(19):5009-22. doi: 10.1158/1078-0432.CCR-14-1122-T.


CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.

Lin X, Gudgeon NH, Hui EP, Jia H, Qun X, Taylor GS, Barnardo MC, Lin CK, Rickinson AB, Chan AT.

Cancer Immunol Immunother. 2008 Jul;57(7):963-75.


Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.

Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.

Oncol Rep. 2004 Oct;12(4):725-31.


Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.

Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C, Martin R.

Brain. 2006 Jun;129(Pt 6):1493-506.


Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.

Zheng Y, Parsonage G, Zhuang X, Machado LR, James CH, Salman A, Searle PF, Hui EP, Chan AT, Lee SP.

Cancer Immunol Res. 2015 Oct;3(10):1138-47. doi: 10.1158/2326-6066.CIR-14-0203-T. Erratum in: Cancer Immunol Res. 2016 Feb;4(2):173-4.


Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A, Chang WC, Gonzalez S, Smith D, Forman SJ, Jensen MC.

Blood. 2005 Feb 15;105(4):1622-31.


Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.

Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM.

J Immunol. 2005 Sep 15;175(6):4137-47. Erratum in: J Immunol. 2005 Nov 1;175(9):6238.


Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.

Smith C, Cooper L, Burgess M, Rist M, Webb N, Lambley E, Tellam J, Marlton P, Seymour JF, Gandhi M, Khanna R.

J Immunol. 2006 Oct 1;177(7):4897-906.


CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.

Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, Taylor GS, Rickinson AB.

Blood. 2009 Jul 23;114(4):807-15. doi: 10.1182/blood-2008-12-194043.


Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.

Leen A, Ratnayake M, Foster A, Heym K, Ahmed N, Rooney CM, Gottschalk S.

J Immunother. 2007 Jan;30(1):96-107.


A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells.

Taylor GS, Long HM, Haigh TA, Larsen M, Brooks J, Rickinson AB.

J Immunol. 2006 Sep 15;177(6):3746-56.

Items per page

Supplemental Content

Support Center